Defining the dose of a new renoprotective drug with the optimal benefit-to-risk ratio is an important consideration for drug developers and physicians. Have we learned from past experiences?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 65, 2309–2320 (2004).
Jurgens, C. M. J. et al. The ETA-selective antagonist SPP301 reduces proteinuria in patients with diabetic nephropathy on top of high dose AT1 receptor blockade [abstract]. Kidney Blood Pressure Research 26, 314(A) (2003).
Benigni, A. et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47, 450–456 (1998).
Cosenzi, A. et al. Nephroprotective effect of bosentan in diabetic rats. J. Cardiovasc. Pharmacol. 42, 752–756 (2003).
Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655–664 (2009).
European Medicines Evaluation Agency. ICH topic E4: Dose Response Information to Support Drug Registration [online], (1994).
de Zeeuw, D. & Lambers-Heerspink, H. J. Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score? J. Am. Soc. Nephrol. 20, 688–689 (2009).
Food and Drug Administration. Maximum Recommended Therapeutic Dose (MRTD) database [online], (2009).
Heel, R. C., Brogden, R. N., Speight, T. M. & Avery, G. S. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20, 409–452 (1980).
Viberti, G. et al. Efficacy and safety of the endothelin receptor antagonist avosentan in diabetic nephropathy [abstract]. J. Am. Soc. Nephrol. 19, 965A (2008).
Maillard, M., Wang, Q., Baltatu, O. C. & Burnier, M. Do endothelin receptor antagonists induce edema through an extravasation of fluids? Evidence from an experiment in bi-nephrectomized rats [abstract]. J. Hypertens. 26 (Suppl. 1), S371 (2008).
Acknowledgements
The authors would like to thank Dr. R. T. Gansevoort, University Medical Centre Groningen, Groningen, The Netherlands, for collecting the data presented in Figure 1.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Heerspink, H., de Zeeuw, D. Defining the optimal dose of a new drug: a crucial decision. Nat Rev Nephrol 5, 498–500 (2009). https://doi.org/10.1038/nrneph.2009.111
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.111
